Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New eczema cream shows promise in large trial

NCT ID NCT05032859

Disease control Sponsor: Organon and Co Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested a cream called tapinarof in 406 people aged 2 and older with moderate to severe eczema. Participants applied the cream or a placebo once daily for 8 weeks. The main goal was to see if the cream could make skin clear or almost clear. Results are being analyzed to determine how well it works and if it is safe.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
tapinarof cream, 1%
What this could lead to
If successful, this could provide a new topical treatment option for people with moderate to severe eczema, helping clear skin and reduce symptoms.
What could go wrong
This is a completed Phase 3 trial, but results may not apply to all patients. Side effects or lack of long-term benefit are possible, and the cream may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

406 people

The number who actually took part.

Started

Sep 2021

Finished

Feb 2023

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

2 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male and female subjects ages 2 and above with clinical diagnosis of AD * Subject with atopic dermatitis covering ≥5% and ≤ 35% of the BSA * A vIGA-AD score of ≥3 at screening and baseline * An EASI score of ≥6 at screening and baseline * Atopic dermatitis present for at least 6 months for ages 6 years old and above or 3 months for ages 2 to 5 years old * Female subjects of childbearing potential who are engaging in sexual activity that could lead to pregnancy should use acceptable birth control methods * Must not be pregnant * Subject, subject's parent, or legal representative must be capable of giving written informed consent/assent Exclusion Criteria: * Immunocompromised at screening * Chronic or acute systemic or superficial infection requiring treatment with systemic antibacterials or antifungals within one week prior to baseline visit * Significant dermatological or inflammatory condition other than AD that, in the Investigator's opinion, would make it difficult to interpret data or assessments during the study * Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥2.0x the upper limit of normal (ULN). * Screening total bilirubin \> 1.5x ULN * Current or chronic history of liver disease * Current or history of cancer within 5 years except for adequately treated cutaneous basal cell carcinoma, squamous cell carcinoma or carcinoma in situ of the cervix * Subjects who would not be considered suitable for topical therapy * Use of any prohibited medication or procedure within the indicated period before the baseline visit including other investigational product within 30 days or 5 half-lives of the investigational product (whichever is longer) * History of or ongoing serious illness or medical, physical, or psychiatric condition(s) that, in the Investigator's opinion, may interfere with the subject's participation in the study, interpretation of results, or ability to understand and give informed consent. * Pregnant or lactating females * History of sensitivity to the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the -Investigator or Medical Monitor, contraindicates their participation * Previous known participation in a clinical study with tapinarof (previously known as GSK2894512 and WBI-1001)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atopic dermatitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atopic eczema Eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atopic dermatitis

Contacts and locations

Locations

  • Dermanvant Investigative Site

    Brooklyn, New York, 11203, United States

  • Dermavant Investigative Site

    Birmingham, Alabama, 35244, United States

  • Dermavant Investigative Site

    Scottsdale, Arizona, 85255, United States

  • Dermavant Investigative Site

    Scottsdale, Arizona, 85260, United States

  • Dermavant Investigative Site

    Fort Smith, Arkansas, 72916, United States

  • Dermavant Investigative Site

    Cerritos, California, 90702, United States

  • Dermavant Investigative Site

    Huntington Beach, California, 92647, United States

  • Dermavant Investigative Site

    Lancaster, California, 93534, United States

  • Dermavant Investigative Site

    Long Beach, California, 90806, United States

  • Dermavant Investigative Site

    Los Angeles, California, 90045, United States

  • Dermavant Investigative Site

    San Diego, California, 92123, United States

  • Dermavant Investigative Site

    San Francisco, California, 94115, United States

  • Dermavant Investigative Site

    Santa Ana, California, 92701, United States

  • Dermavant Investigative Site

    Santa Monica, California, 90404, United States

  • Dermavant Investigative Site

    Boca Raton, Florida, 33428, United States

  • Dermavant Investigative Site

    Delray Beach, Florida, 33484, United States

  • Dermavant Investigative Site

    Jacksonville, Florida, 32256, United States

  • Dermavant Investigative Site

    Miami, Florida, 33165, United States

  • Dermavant Investigative Site

    Miami, Florida, 33173, United States

  • Dermavant Investigative Site

    Miami Lakes, Florida, 33014, United States

  • Dermavant Investigative Site

    Tampa, Florida, 33607, United States

  • Dermavant Investigative Site

    Snellville, Georgia, 30078, United States

  • Dermavant Investigative Site

    Evansville, Indiana, 47715, United States

  • Dermavant Investigative Site

    Overland Park, Kansas, 66210, United States

  • Dermavant Investigative Site

    Lexington, Kentucky, 40517, United States

  • Dermavant Investigative Site

    Louisville, Kentucky, 40241, United States

  • Dermavant Investigative Site

    Baton Rouge, Louisiana, 70808, United States

  • Dermavant Investigative Site

    Baton Rouge, Louisiana, 70809, United States

  • Dermavant Investigative Site

    New Orleans, Louisiana, 70115, United States

  • Dermavant Investigative Site

    Rockville, Maryland, 20850, United States

  • Dermavant Investigative Site

    Detroit, Michigan, 48202, United States

  • Dermavant Investigative Site

    Lincoln, Nebraska, 68516, United States

  • Dermavant Investigative Site

    Omaha, Nebraska, 68114, United States

  • Dermavant Investigative Site

    Las Vegas, Nevada, 89148, United States

  • Dermavant Investigative Site

    East Windsor, New Jersey, 08520, United States

  • Dermavant Investigative Site

    Watertown, New York, 13601, United States

  • Dermavant Investigative Site

    Charlotte, North Carolina, 28277, United States

  • Dermavant Investigative Site

    Dayton, Ohio, 45414, United States

  • Dermavant Investigative Site

    Mason, Ohio, 45040, United States

  • Dermavant Investigative Site

    Mayfield Heights, Ohio, 44124, United States

  • Dermavant Investigative Site

    Tulsa, Oklahoma, 74114, United States

  • Dermavant Investigative Site

    Medford, Oregon, 97504, United States

  • Dermavant Investigative Site

    Portland, Oregon, 97210, United States

  • Dermavant Investigative Site

    Portland, Oregon, 97239, United States

  • Dermavant Investigative Site

    East Greenwich, Rhode Island, 02818, United States

  • Dermavant Investigative Site

    Anderson, South Carolina, 29621, United States

  • Dermavant Investigative Site

    North Charleston, South Carolina, 29420, United States

  • Dermavant Investigative Site

    Spartanburg, South Carolina, 29303, United States

  • Dermavant Investigative Site

    Memphis, Tennessee, 38119, United States

  • Dermavant Investigative Site

    Bellaire, Texas, 77401, United States

  • Dermavant Investigative Site

    Dripping Springs, Texas, 78620, United States

  • Dermavant Investigative Site

    Grapevine, Texas, 76051, United States

  • Dermavant Investigative Site

    Houston, Texas, 77004, United States

  • Dermavant Investigative Site

    Houston, Texas, 77061, United States

  • Dermavant Investigative Site

    San Antonio, Texas, 78213, United States

  • Dermavant Investigative Site

    Webster, Texas, 77598, United States

  • Dermavant Investigative Site

    Spokane, Washington, 99202, United States

  • Dermavant Investigative Site

    Surrey, British Columbia, V3R 6A7, Canada

  • Dermavant Investigative Site

    Barrie, Ontario, L4M 7G1, Canada

  • Dermavant Investigative Site

    Markham, Ontario, L3P 1X3, Canada

  • Dermavant Investigative Site

    Waterloo, Ontario, N2J 1C4, Canada

  • Dermavant Investigative Site

    Windsor, Ontario, N8W 1E6, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.